金黄色葡萄球菌
抗生素
菌血症
微生物学
赖氨酸
耐甲氧西林金黄色葡萄球菌
达托霉素
万古霉素
医学
葡萄球菌感染
生物
细菌
噬菌体
大肠杆菌
基因
生物化学
遗传学
作者
Raymond Schuch,Han M. Lee,Brigitte Schneider,Karen Sauve,Christina Law,Babar Khalid Khan,Jimmy A. Rotolo,Yuki Horiuchi,Daniel E. Couto,Assaf Raz,Vincent A. Fischetti,David B. Huang,Robert C. Nowinski,Michael Wittekind
标识
DOI:10.1093/infdis/jit637
摘要
Lysins are bacteriophage-derived enzymes that degrade bacterial peptidoglycans. Lysin CF-301 is being developed to treat Staphylococcus aureus because of its potent, specific, and rapid bacteriolytic effects. It also demonstrates activity on drug-resistant strains, has a low resistance profile, eradicates biofilms, and acts synergistically with antibiotics. CF-301 was bacteriolytic against 250 S. aureus strains tested including 120 methicillin-resistant S. aureus (MRSA) isolates. In time-kill studies with 62 strains, CF-301 reduced S. aureus by 3-log10 within 30 minutes compared to 6-12 hours required by antibiotics. In bacteremia, CF-301 increased survival by reducing blood MRSA 100-fold within 1 hour. Combinations of CF-301 with vancomycin or daptomycin synergized in vitro and increased survival significantly in staphylococcal-induced bacteremia compared to treatment with antibiotics alone (P < .0001). Superiority of CF-301 combinations with antibiotics was confirmed in 26 independent bacteremia studies. Combinations including CF-301 and antibiotics represent an attractive alternative to antibiotic monotherapies currently used to treat S. aureus bacteremia.
科研通智能强力驱动
Strongly Powered by AbleSci AI